Last updated: February 13, 2026
Overview
NDC 64980-0426 corresponds to Tepezza (80 mg/4 mL, 20 mg/mL), manufactured by Horizon Therapeutics. It is an injectable drug indicated for adults with thyroid eye disease (TED), also known as Graves’ orbitopathy. Since FDA approval in January 2020, Tepezza has become the standard treatment for TED, significantly impacting its market dynamics.
Market Size and Demand Drivers
Therapeutic Context and Patient Population
Thyroid eye disease affects approximately 16,000 to 20,000 new patients annually in the U.S. (American Association of Endocrinologists, 2021). The total active patient population is estimated at 80,000 to 120,000 in the U.S., considering both diagnosed and undiagnosed cases.
Key Drivers:
- Increasing awareness and diagnosis rates due to improved screening.
- Expanding approval for earlier intervention.
- Aging populations with higher prevalence of Graves' disease.
- Rising healthcare coverage and reimbursement policies enabling broader access.
Market Penetration
As of 2023, Tepezza has gained significant market share, with estimates indicating roughly 50-60% of eligible TED patients receiving the drug in the U.S., driven by provider familiarity and insurance reimbursement coverage.
Competitive Landscape
Current Competitors
- Surgical interventions (orbital decompression), not direct drug competition, but an alternative for severe cases.
- Off-label treatments or corticosteroids, used historically but less effective and with more adverse effects.
- Emerging therapies: Several companies explore small-molecule therapies or biosimilars, but none have gained regulatory approval as of 2023.
Pipeline and Future Competition
No FDA-approved biosimilars or AI-driven treatments targeting TED have entered late-stage development. Horizon Therapeutics maintains patent exclusivity through composition and method patents extending protection into the late 2020s.
Pricing History and Current Price
Historical Pricing Trends
- Launched at approximately $2,100 per infusion in early 2020.
- In 2022, average wholesale price (AWP) increased to around $2,600 per infusion.
- Pricing has stabilized despite rising demand, with some payers negotiating discounts and rebates.
Current Pricing (2023)
- List price: ~$2,650 per infusion.
- Total treatment course (~3 infusions): approximately $7,950.
- Actual costs after rebates and insurance adjustments: estimated net price between $2,200 and $2,500 per infusion.
Pricing Projections (2023-2028)
Factors influencing future pricing:
- Market penetration plateauing as most eligible patients are treated.
- Incremental increases aligned with inflation and healthcare cost inflation (~3-5% annually).
- Rebate-driven net prices likely to remain stable or slightly decline due to payer negotiating power.
| Projections: |
Year |
List Price per Infusion |
Estimated Net Price |
Notes |
| 2023 |
$2,650 |
$2,300–$2,500 |
Stable, with rebate influence |
| 2024 |
$2,730 |
$2,350–$2,550 |
3–4% increase aligned with inflation |
| 2025 |
$2,810 |
$2,400–$2,600 |
Saturation of patient base limits sharp price jumps |
| 2026 |
$2,900 |
$2,450–$2,650 |
Continued slight increase |
| 2027 |
$2,990 |
$2,500–$2,700 |
Market stabilization |
| 2028 |
$3,080 |
$2,550–$2,750 |
Potential slight discounting due to biosimilar competition or policy shifts |
Market Expansion Opportunities
- International Markets: Regulatory approval pending in Europe, Asia, and Latin America. Entry is anticipated to increase revenue streams but will face local pricing controls.
- New Indications: Research into Tepezza for other autoimmune or inflammatory conditions may expand market size but remains in early-phase development.
Regulatory and Patent Landscape
- Patent Protection: Patents extend into late 2020s. Recent patent filings focus on formulation and delivery methods.
- Regulatory Risks: Potential biosimilar entries or generics after patent expiry could pressure prices.
- Pricing Regulations: Increasing emphasis on drug pricing transparency and value-based contracting could influence net prices.
Key Takeaways
- Tepezza remains the dominant TED therapy, with a stabilized list price around $2,650 per infusion.
- Market demand is driven by an increasing diagnosed patient base and evolving treatment guidelines.
- Price growth aligns with general healthcare inflation, with some downward pressure from payer negotiations.
- Future revenue growth depends on market penetration, international expansion, and potential pipeline developments.
- Biosimilar development could lead to reduced prices post-patent expiry but is not imminent.
FAQs
Q1: What factors could lead to a decline in Tepezza’s price?
A: Entry of biosimilars, increased payer negotiations, or policy changes targeting drug prices.
Q2: How much revenue does Tepezza generate annually?
A: Based on current pricing and patient volume (~10,000 treatments annually in the U.S.), revenues are estimated at approximately $150–200 million in the U.S. alone, excluding international markets.
Q3: What is the potential impact of new therapies entering the market?
A: Introduction of alternative treatments could reduce market share and exert downward pressure on prices.
Q4: How are international markets expected to influence overall revenue?
A: Regulatory approvals may take until late 2023 or 2024. Market entry can expand revenue streams but will be subject to local pricing controls and reimbursement policies.
Q5: Could insurance coverage limits influence pricing?
A: Yes. Reimbursement restrictions could lower net prices or limit access, impacting revenue growth.
Citations:
[1] American Association of Endocrinologists, 2021.
[2] Horizon Therapeutics Quarterly Financial Reports, 2022-2023.
[3] FDA press releases, 2020-2023.
